A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity

The delivery of therapeutic peptides and proteins is often challenged by a short half-life, and thus the need for frequent injections that limit efficacy, reduce patient compliance and increase treatment cost. Here, we demonstrate that a single subcutaneous injection of site-specific (C-terminal) co...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yizhi, Simakova, Antonina, Ganson, Nancy J., Li, Xinghai, Luginbuhl, Kelli M., Özer, Imran, Liu, Wenge, Hershfield, Michael S., Matyjaszewski, Krzysztof, Chilkoti, Ashutosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627778/
https://www.ncbi.nlm.nih.gov/pubmed/28989813
http://dx.doi.org/10.1038/s41551-016-0002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627778/
https://www.ncbi.nlm.nih.gov/pubmed/28989813
http://dx.doi.org/10.1038/s41551-016-0002

Ejemplares similares